Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026)
Enanta Pharmaceuticals (ENTA) reported Net Margin of 76.29% for Q1 2026, up 7542.0% on a YoY basis from 1.0% in Q1 2025, and down 18.96% quarter-over-quarter from 64.13% in Q4 2025.
Enanta Pharmaceuticals (ENTA) Net Margin (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals has reported Net Margin for 15 years, with the latest figure at 76.29% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 7542.0% year-over-year to 76.29%; the trailing twelve-month figure through Mar 2026 stood at 89.56% (up 5971.0% YoY), and the FY2025 full-year result was 125.36%, up 4593.0% from the prior year.
- Net Margin for Q1 2026 stood at 76.29%, down from 64.13% in the prior quarter.
- The five-year high for Net Margin was 64.13% in Q4 2025, with the low at 211.62% in Q1 2023.
- Historically, Net Margin has averaged 146.99% across 5 years, with a median of 148.46% in 2023.
- Annual changes were most pronounced in 2022 — Net Margin surged 21773 bps — and 2023, when it slumped 6266 bps.
- Enanta Pharmaceuticals' Net Margin stood at 122.9% in 2022, then plunged by 51 bps to 185.56% in 2023, then advanced by 29 bps to 131.43% in 2024, then jumped by 51 bps to 64.13% in 2025, then decreased by 19 bps to 76.29% in 2026.
- The last three Net Margin figures came in at 76.29% (Q1 2026), 64.13% (Q4 2025), and 123.64% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 365.48 Mn | 201.71 Mn | - | -76.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.29% |
| Dec 31, 2025 | -64.13% |
| Sep 30, 2025 | -123.64% |
| Jun 30, 2025 | -99.68% |
| Mar 31, 2025 | -151.71% |
| Dec 31, 2024 | -131.43% |
| Sep 30, 2024 | -196.00% |
| Jun 30, 2024 | -126.08% |
| Mar 31, 2024 | -182.70% |
| Dec 31, 2023 | -185.56% |
| Sep 30, 2023 | -148.46% |
| Jun 30, 2023 | -206.78% |
| Mar 31, 2023 | -211.62% |
| Dec 31, 2022 | -122.90% |
| Sep 30, 2022 | -129.68% |
| Jun 30, 2022 | -162.74% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -108.92% |
| Sep 30, 2021 | -347.41% |
| Jun 30, 2021 | -111.10% |